Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for patients with reversible airway obstruction, primarily in asthma and chronic obstructive pulmonary disease.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate is a bronchodilator that acts on the β2‑adrenergic pathway to relax airway smooth muscle. - Asthma: improves control of symptoms and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases rescue‑inhaler use. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Formoterol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Throat irritation: mild discomfort or dryness in the throat. - Cough: transient coughing after inhalation. - Headache: mild to moderate headache. - Tremor: fine muscle tremor, often of the hands. - Palpitations: sensation of rapid or irregular heartbeat. - Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiovascular events: arrhythmia, tachycardia, or hypertension. - Hypokalemia: low blood potassium levels. - Hyperglycaemia: elevated blood glucose, especially in diabetic patients.

When using Oxis Turbohaler, consider the following safety measures: - Assess asthma/COPD severity: ensure the patient is appropriate for a long‑acting β2‑agonist. - Review cardiovascular history: patients with arrhythmia or hypertension need close monitoring. - Avoid excessive use: limit rescue inhaler reliance to prevent tolerance. - Monitor for paradoxical bronchospasm: discontinue if breathing worsens after use. - Educate on inhaler technique: proper use maximises drug delivery and reduces side effects. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Formoterol can interact with several drug classes, requiring attention to avoid reduced efficacy or increased adverse effects.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension when combined with sympathomimetic drugs.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia caused by β2‑agonist activity. - Theophylline: additive bronchodilator effect can increase risk of tremor and tachycardia. - Corticosteroids inhaled: may enhance systemic absorption, requiring dose adjustment. - Anticholinergic bronchodilators: combined therapy may increase cardiovascular load. - Certain antidepressants (e.g., SSRIs): monitor for heightened tachycardia.